|View printer-friendly version|
|April 24, 2013 7:00 a.m.|
|Teva Establishes Global Specialty Medicines Group|
Move is part of strategic plan to optimize commercialization
Newly created group to utilize strong locally-led Generics presence to leverage Teva's globally-based Specialty offering
"The newly created Global Specialty Medicines group significantly reinforces Teva's commitment to our patients, customers, and healthcare providers, as it combines the strong local presence we have established in high-quality and accessible generics with our global scale and capabilities in specialty medicines," said Dr. Levin. "The GSM group will work seamlessly with our regional generics teams. They will complement each other and establish a single, differentiated Teva presence in the market. The creation of this group is a stepping stone in our strategy to optimize our commercialization, and it paves the path forward to make Teva the most indispensable medicines company for the world."
Dr. Koremans stated, “Teva has an impressive portfolio of Specialty medicines, and this move will further emphasize and strengthen our leadership and innovation in this field. Teva’s unique capabilities in Specialty pharmaceuticals are now concentrated in the new GSM group, so we can deliver more effectively on our commitment to our patients and other stakeholders.”
Teva also announced that Mr.
Dr. Levin welcomed the promotion of Mr. Bhattacharjee, saying: “We welcome Dipankar to his new role. He is a terrific leader and will focus on improving and enhancing the European Generics operations, while building and maintaining close interactions with the GSM team."
As part of the changes implemented, Mr.
Dipankar Bhattacharjee joined Teva in 2009. Prior to joining Teva as